| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Glaxo Wellcome |
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002284 |
Purpose
To determine whether zidovudine (AZT) in conjunction with bone marrow transplantation prevents the reinfection of donor hematopoietic/lymphoid cells in patients with positive HTLV III antibody and large cell/diffuse histiocytic lymphoma. Patients who are candidates will be evaluated for HTLV III activity and drug levels.
| Condition | Intervention |
|
Lymphoma, Non-Hodgkin HIV Infections |
Drug: Zidovudine |
| MedlinePlus related topics: | AIDS Bone Marrow Transplantation Lymphoma |
| ChemIDplus related topics: | Zidovudine |
| Study Type: | Interventional |
| Study Design: | Treatment, Dose Comparison |
| Official Title: | A Pilot Study To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients Receiving a Bone Marrow Transplant |
Eligibility
| Ages Eligible for Study: | 12 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Exclusion Criteria
Co-existing Condition:
Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.
Concurrent Medication:
Excluded:
Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.
Patients must be:
Contacts and Locations More Information
| Study ID Numbers: | 014A, 006 |
| First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00002284 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|
